보고서 요약(국문)

개요
전 세계 반응성 기도 질환 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
반응성 기도 질환은 폐로 공기를 들여오는 기관지가 자극 물질에 과민 반응하여 부어오르고 호흡 곤란을 일으키는 질환입니다. 반응성 기도 질환은 천식 증상을 보이는 어린아이들에게서 흔히 진단됩니다.
반응성 기도 질환은 에어로졸, 가스, 연기 또는 증기에 노출된 후 24시간 이내에 알레르겐이 없는 상태에서 발생하는 천식과 유사한 증상입니다. 반응성 기도 질환으로 진단받은 사람들은 일반적으로 천식으로 인해 발생할 수 있는 천명, 기침, 호흡 곤란 및 가래 생성 등의 병력이 있습니다.

시장 동향
호흡기 질환 유병률 증가
호흡기 질환 유병률의 증가는 시장 성장의 중요한 동인으로 작용합니다. 가장 흔한 만성 호흡기 질환 두 가지는 천식과 만성 폐쇄성 폐질환(COPD)입니다. 이 두 질환 모두 폐의 기도에 영향을 미치며, 기도 협착으로 인해 호흡곤란과 천명음이 반복적으로 발생하는 것이 특징입니다.
예를 들어, 세계보건기구(WHO)의 2023년 보고서에 따르면, 천식은 약 2억 6,200만 명에게 영향을 미치고 45만 5천 명의 사망자를 발생시켰습니다. 또한, 만성 호흡기 질환은 전 세계적으로 4억 5,460만 명의 환자와 400만 명의 사망자를 발생시켜 세 번째 주요 사망 원인이었습니다.
더불어, 미국 천식 및 알레르기 재단(Asthma and Allergy Foundation of America)에 따르면, 성인 여성의 약 10.8%, 성인 남성의 약 6.5%가 천식을 앓고 있습니다. 천식은 어린이에게 가장 흔한 만성 질환입니다. 18세 미만 어린이 약 450만 명이 천식을 앓고 있습니다.

또한, 반응성 기도 질환 치료제에 대한 임상 시험 증가 및 신제품 출시와 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
치료 약물 관련 부작용
베클로메타손과 같은 치료 약물은 코막힘, 몸살, 호흡 곤란, 쉰 목소리 등의 부작용을 유발할 수 있습니다. 일반적으로 의학적 치료가 필요하지 않은 부작용도 발생할 수 있습니다. 경련, 가슴 압박감, 심한 출혈, 눈과 광대뼈 주변의 통증 또는 압통은 드문 부작용입니다.
세분화 분석
전 세계 반응성 기도 질환 시장은 질환, 치료법, 유통 채널 및 지역별로 세분화됩니다.
기관지 확장제 부문은 시장 점유율의 약 43.9%를 차지했습니다.
기관지 확장제 부문은 신제품 출시 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 기관지 확장제(흡입기)는 기도를 이완시키는 데 도움을 줍니다. 의사들은 일반적으로 천식과 만성 폐쇄성 폐질환(COPD) 치료를 위해 기관지 확장제를 처방합니다.
예를 들어, 2023년 7월, 테바 영국(Teva UK)은 영국에서 새로운 GoResp Digihaler 시스템을 출시했습니다. GoResp Digihaler는 흡입 유량 분류를 포함하여 환자의 흡입기 사용 및 사용 능력에 대한 객관적인 데이터를 감지하고 기록하는 내장 센서가 있는 최초의 통합 흡입기입니다.
또한, 2023년 7월, 독일 루핀(Lupin)의 완전 자회사인 호르모산 파마(Hormosan Pharma GmbH)는 유럽에서 가압식 정량 흡입기인 루포벡(Luforbec)을 출시했습니다. 루포벡은 흡입 코르티코스테로이드와 장기 작용 베타2-작용제 사용이 적합한 성인 천식 및 COPD 치료에 사용됩니다. 따라서 위의 요인들로 인해 해당 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

지리적 분석
북미는 전 세계 반응성 기도 질환 시장에서 상당한 점유율을 차지할 것으로 예상됩니다.
북미는 기관지확장증 유병률 증가, 제품 승인, 의료비 지출 증가 등의 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 미국에서는 약 35만~50만 명의 성인이 기관지확장증을 앓고 있는 것으로 추산됩니다. 기관지확장증 유병률은 연령이 증가함에 따라 높아지며, 60세 이후에는 8~10배 증가합니다.
또한, 2023년 1월에는 18세 이상 천식 환자의 기관지 수축 악화 위험을 줄이기 위한 치료제인 에어수프라(Airsupra)가 미국에서 승인되었습니다. 에어수프라는 알부테롤(단기 작용 베타2 효능제, SABA)과 부데소니드를 함유한 최초의 가압식 정량 흡입기(pMDI) 고정 용량 복합 응급 약물입니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 반응성 기도 질환 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 광범위한 봉쇄와 제한 조치가 시행되면서 전 세계적으로 정기적인 진단, 치료, 신약 출시 및 상담에 차질이 생겼습니다. 팬데믹 발생으로 많은 제약 회사나 의료기기 제조업체는 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 출근하지 못하는 상황이 발생했습니다. 따라서 이러한 요인들로 인해 반응성 기도 질환 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.

시장 세분화
질환별
• 천식
• 기관지확장증
• 만성 폐쇄성 폐질환(COPD)
• 낭포성 섬유증
치료법별
• 기관지 확장제
• 코르티코스테로이드
o 베클로메타손
o 플루티카손
o 부데소니드
o 모메타손
• 산소 요법
• 에피네프린 주사
유통 채널별
• 소매 약국
• 병원 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 GlaxoSmithKline Plc. 등이 있습니다. Cipla Ltd, AstraZeneca Plc, Niksan Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck KGaA, Lupin Ltd., Hikma Pharmaceuticals Plc. 및 Merit Pharmaceutical 등이 있습니다.
주요 개발 사항
• 2023년 6월, Phil Inc.는 Teva Pharmaceuticals와 협력하여 Digihaler 흡입기 제품군의 접근성을 개선하는 새로운 프로그램을 시작했습니다. 이 프로그램의 목표는 환자들이 Digihaler 약물을 빠르고 간편하며 저렴하게 처방받고 재처방받을 수 있도록 지원하는 것입니다.

• 2023년 11월, Aurobindo Pharma는 미국 FDA로부터 소아 천식 치료용 제네릭 의약품인 부데소니드 흡입 현탁액의 판매 승인을 받았습니다.

보고서 구매 이유

• 질환, 치료법, 유통 채널 및 지역별 글로벌 반응성 기도 질환 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해.

• 전 세계 반응성 기도 질환 시장의 모든 부문에 대한 다양한 데이터가 담긴 엑셀 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공

전 세계 반응성 기도 질환 시장 보고서는 약 58개의 표, 58개의 그림, 185페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Reactive Airway Disease Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Reactive airway disease occurs when the bronchial tubes that bring air into the lungs overreact to an irritant, swell, and cause breathing problems. Reactive airway disease is often diagnosed in young children who are showing signs of asthma.
Reactive airway disease is an asthma-like episode that develops in the absence of an allergen within 24 hours of exposure to an aerosol, gas, fumes, or vapor. Individuals who are typically labeled as having reactive airway disease generally have a history of wheezing, coughing, dyspnea, and production of sputum that can be caused by asthma.
Market Dynamics
Increasing prevalence of respiratory illness
The increasing prevalence of respiratory illness acts as a significant driver for market growth. The two most common chronic respiratory diseases are asthma and chronic obstructive pulmonary disease (COPD). These both affect the airways in the lungs which is characterized by recurrent attacks of breathlessness and wheezing due to airway narrowing.
For instance, according to the World Health Organization Report 2023, asthma affected an estimated 262 million people and caused 455,000 deaths. Also, chronic respiratory diseases were the third-leading cause of death, responsible for 4.0 million deaths with a prevalence of 454.6 million cases globally.
Additionally, according to the Asthma and Allergy Foundation of America, approximately 10.8% of adult females and 6.5% of adult males suffer from asthma. It is the most common chronic illness among kids. Approximately 4.5 million children under the age of 18 suffer from asthma.
Furthermore, significant growth drivers such as the rising clinical trials for reactive airway disease drugs, and the new product launches are expected to drive the market in the forecast period.
Side effects associated with treatment medications
The treatment medications like beclomethasone can cause congestion, body aches, congestion, difficulty in breathing, and hoarseness. Some side effects can also occur that usually do not need medical attention. Cramps, tightness of the chest, heavy bleeding, and pain or tenderness around the eyes and cheekbones are the less common side effects.
Segment Analysis
The global reactive airway disease market is segmented based on condition, treatment, distribution channel, and region.
The bronchodilators segment accounted for approximately 43.9% of the market share
The bronchodilators segment is expected to hold the largest market share over the period forecast due to the increasing number of product launches. Bronchodilators (inhalers) help in relaxing the airways. Doctors commonly prescribe bronchodilators to treat asthma and chronic obstructive pulmonary disease (COPD).
For instance, in July 2023, Teva UK launched a new GoResp Digihaler system in the United Kingdom. GoResp Digihaler is the first integrated inhaler with built-in sensors that detect and record objective data on the patient’s use and ability to use their inhaler including inspiratory flow classification.
Additionally, in July 2023, Hormosan Pharma GmbH, a wholly-owned subsidiary of the Lupin company in Germany, launched Luforbec, a pressurized metered dose inhaler in the European nation. Luforbec is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global reactive airway disease market share
North America has maintained a significant market proportion due to factors such as the rising prevalence of bronchiectasis, product approvals, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, an estimated 350,000 to 500,000 adults have bronchiectasis in the United States. The prevalence of bronchiectasis increases with age with an 8 to 10 fold difference in prevalence after the age of 60 years.
Additionally, in January 2023, Airsupra was approved in the United States for the treatment of bronchoconstriction to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global reactive airway disease market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the reactive airway disease market is expected to be moderately affected over the forecast period.
Market Segmentation
By Condition
• Asthma
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD)
• Cystic fibrosis
By Treatment
• Bronchodilators
• Corticosteroids
o beclomethasone
o fluticasone
o budesonide
o mometasone
• Oxygen therapy
• Epinephrine injection
By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include GlaxoSmithKline Plc., Cipla Ltd, AstraZeneca Plc, Niksan Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck KGaA, Lupin Ltd., Hikma Pharmaceuticals Plc. and Merit Pharmaceutical among others.
Key Developments
• In June 2023, Phil Inc. in partnership with Teva Pharmaceuticals launched a new program to improve access to the Digihaler family of inhalers. The goal of the program is to help enable patients to receive and refill their Digihaler medication quickly, easily, and affordably.
• In November 2023, Aurobindo Pharma received approval for Budesonide Inhalation Suspension from the U.S. FDA to market a generic medication to treat asthma in children.
Why Purchase the Report?
• To visualize the global reactive airway disease market segmentation based on condition, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global reactive airway disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global reactive airway disease market report would provide approximately 58 tables, 58 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Condition
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of respiratory illness
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with treatment medications
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Condition
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
7.1.2. Market Attractiveness Index, By Condition
7.2. Asthma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bronchiectasis
7.4. Chronic obstructive pulmonary disease (COPD)
7.5. Cystic fibrosis
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Bronchodilators*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Corticosteroids
8.3.1. beclomethasone
8.3.2. fluticasone
8.3.3. budesonide
8.3.4. mometasone
8.4. Oxygen therapy
8.5. Epinephrine injection
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Retail Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospital Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. GlaxoSmithKline Plc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Cipla Ltd
12.3. AstraZeneca Plc
12.4. Niksan Pharmaceutical
12.5. Teva Pharmaceutical Industries Ltd.
12.6. Merck KGaA
12.7. Lupin Ltd
12.8. Hikma Pharmaceuticals Plc
12.9. Merit Pharmaceutical
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

GlaxoSmithKline Plc., 4.	Key Developments, Cipla Ltd, AstraZeneca Plc, Niksan Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck KGaA, Lupin Ltd, Hikma Pharmaceuticals Plc, Merit Pharmaceutical

표 목록 (Tables)

List of Tables

Table 1 Global Reactive Airway Disease Market Value, By Condition, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Reactive Airway Disease Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Reactive Airway Disease Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Reactive Airway Disease Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Reactive Airway Disease Market Value, By Condition, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 7 Global Reactive Airway Disease Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Reactive Airway Disease Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Reactive Airway Disease Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Reactive Airway Disease Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 14 North America Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Reactive Airway Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 18 South America Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 South America Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Reactive Airway Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 22 Europe Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Reactive Airway Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Reactive Airway Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Reactive Airway Disease Market Value, By Condition, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Reactive Airway Disease Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Reactive Airway Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 GlaxoSmithKline Plc: Overview

Table 33 GlaxoSmithKline Plc: Product Portfolio

Table 34 GlaxoSmithKline Plc: Key Developments

Table 35 Cipla Ltd: Overview

Table 36 Cipla Ltd: Product Portfolio

Table 37 Cipla Ltd: Key Developments

Table 38 AstraZeneca Plc: Overview

Table 39 AstraZeneca Plc: Product Portfolio

Table 40 AstraZeneca Plc: Key Developments

Table 41 Niksan Pharmaceutical: Overview

Table 42 Niksan Pharmaceutical: Product Portfolio

Table 43 Niksan Pharmaceutical: Key Developments

Table 44 Teva Pharmaceutical Industries Ltd.: Overview

Table 45 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 46 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 47 Merck KGaA: Overview

Table 48 Merck KGaA: Product Portfolio

Table 49 Merck KGaA: Key Developments

Table 50 Lupin Ltd: Overview

Table 51 Lupin Ltd: Product Portfolio

Table 52 Lupin Ltd: Key Developments

Table 53 Hikma Pharmaceuticals Plc: Overview

Table 54 Hikma Pharmaceuticals Plc: Product Portfolio

Table 55 Hikma Pharmaceuticals Plc: Key Developments

Table 56 Merit Pharmaceutical: Overview

Table 57 Merit Pharmaceutical: Product Portfolio

Table 58 Merit Pharmaceutical: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 2 Global Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 3 Global Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 4 Global Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Reactive Airway Disease Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Reactive Airway Disease Market Y-o-Y Growth, By Condition, 2023-2031 (%)

Figure 7 Asthma Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 8 Bronchiectasis Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 9 Chronic obstructive pulmonary disease (COPD) Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 10 Cystic fibrosis Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 11 Global Reactive Airway Disease Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 12 Bronchodilators Treatment in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 13 Oxygen therapy Treatment in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 14 Corticosteroids Treatment in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 15 Epinephrine injection Treatment in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 16 Global Reactive Airway Disease Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 17 Retail Pharmacy Distribution Channel in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 18 Hospital Pharmacy Distribution Channel in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 19 Online Pharmacy Distribution Channel in Global Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 20 Global Reactive Airway Disease Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 21 North America Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 22 Asia-Pacific Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 24 South America Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 25 Middle East and Africa Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 26 North America Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 27 North America Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 28 North America Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 29 North America Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 30 North America Reactive Airway Disease Market Share, By Country, 2023 & 2031 (%)

Figure 31 South America Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 32 South America Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 33 South America Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 34 South America Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 35 South America Reactive Airway Disease Market Share, By Country, 2023 & 2031 (%)

Figure 36 Europe Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 37 Europe Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 38 Europe Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 39 Europe Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 40 Europe Reactive Airway Disease Market Share, By Country, 2023 & 2031 (%)

Figure 41 Asia-Pacific Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 43 Asia-Pacific Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 44 Asia-Pacific Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 45 Asia-Pacific Reactive Airway Disease Market Share, By Country, 2023 & 2031 (%)

Figure 46 Middle East & Africa Reactive Airway Disease Market Value, 2022-2031 (US$ Million)

Figure 47 Middle East & Africa Reactive Airway Disease Market Share, By Condition, 2023 & 2031 (%)

Figure 48 Middle East & Africa Reactive Airway Disease Market Share, By Treatment, 2023 & 2031 (%)

Figure 49 Middle East & Africa Reactive Airway Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 50 GlaxoSmithKline Plc: Financials

Figure 51 Cipla Ltd: Financials

Figure 52 AstraZeneca Plc: Financials

Figure 53 Niksan Pharmaceutical: Financials

Figure 54 Teva Pharmaceutical Industries Ltd.: Financials

Figure 55 Merck KGaA: Financials

Figure 56 Lupin Ltd: Financials

Figure 57 Hikma Pharmaceuticals Plc: Financials

Figure 58 Merit Pharmaceutical: Financials

세계 반응성 기도 질환 시장 – 2023-2030

Global Reactive Airway Disease Market - 2023-2030